Towa Pharmaceutical Management
Management criteria checks 1/4
Towa Pharmaceutical's CEO is Itsuro Yoshida, appointed in Jun 1996, has a tenure of 28.5 years. directly owns 2.96% of the company’s shares, worth ¥4.24B. The average tenure of the management team and the board of directors is 0.9 years and 3.5 years respectively.
Key information
Itsuro Yoshida
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 28.5yrs |
| CEO ownership | 3.0% |
| Management average tenure | less than a year |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Is Towa Pharmaceutical (TSE:4553) A Risky Investment?
Nov 13
Towa Pharmaceutical (TSE:4553) Will Pay A Dividend Of ¥30.00
Sep 05Towa Pharmaceutical (TSE:4553) Is Due To Pay A Dividend Of ¥30.00
Aug 15Fewer Investors Than Expected Jumping On Towa Pharmaceutical Co., Ltd. (TSE:4553)
Aug 03Towa Pharmaceutical's (TSE:4553) Earnings Are Weaker Than They Seem
Jul 03CEO
Itsuro Yoshida (73 yo)
28.5yrs
Tenure
Mr. Itsuro Yoshida has been the President at Towa Pharmaceutical Co. Ltd. since June 1996. Mr. Yoshida joined Towa Pharmaceutical Co., Ltd.in May 1979 and served as its Manager of Accounting since May 198...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Representative Director | 28.5yrs | no data | 2.96% ¥ 4.2b | |
| Executive Officer and GM of Accounting & Finance Division | less than a year | no data | no data | |
| Executive Officer & GM of Administration Division | less than a year | no data | 0.0024% ¥ 3.5m | |
| Operating Officer & GM of Human Resource Development Center | less than a year | no data | no data | |
| Senior OO & Division Manager of R&D Division and Unit Manager of Innovative Tech Research Unit | less than a year | no data | no data | |
| Director | no data | no data | 0.016% ¥ 22.4m | |
| Senior Executive Officer & GM of Production Division | less than a year | no data | no data | |
| Executive Officer | no data | no data | no data | |
| Executive Officer | no data | no data | no data |
0.9yrs
Average Tenure
70yo
Average Age
Experienced Management: 4553's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Representative Director | 41yrs | no data | 2.96% ¥ 4.2b | |
| Director | 7.5yrs | no data | 0.016% ¥ 22.4m | |
| Director | less than a year | no data | 0.0014% ¥ 2.0m | |
| Independent Outside Director | less than a year | no data | no data | |
| Independent Outside Director | 9.5yrs | no data | no data | |
| Director | 1.5yrs | no data | 0.0045% ¥ 6.4m | |
| Independent Outside Director | 4.5yrs | no data | no data | |
| Independent Outside Director | 3.5yrs | no data | no data | |
| Director | less than a year | no data | 0.0018% ¥ 2.6m |
3.5yrs
Average Tenure
66yo
Average Age
Experienced Board: 4553's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 00:45 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Towa Pharmaceutical Co., Ltd. is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |